Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Contraception
First scientific data for Lybrel presented at ASRM meeting
November 18th, 2005
Wyeth Pharmaceuticals, a division of Wyeth (WYE), announced that four scientific abstracts regarding Lybrel (0.09 mg levonorgestrel/0.02 mg ethinyl estradiol tablets) were presented for the first time at the 61st annual meeting of the American Society for Reproductive Medicine (ASRM) in Montreal, Quebec, Canada. The studies investigated the effects of 0.09 mg levonorgestrel/0.02 mg ethinyl estradiol on ovarian activity, safety and efficacy, endometrial histology, and cycle-related symptoms. The new drug application (NDA) for the study drug, Lybrel, a combination low-dose oral contraceptive designed to be taken daily, 365 days a year, without a placebo phase or pill-free...
Source: Drug Week (2005-11-18)
|
